Reviewing Oculis (OCS) & Its Rivals

Oculis (NASDAQ:OCSGet Free Report) is one of 959 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare Oculis to similar businesses based on the strength of its institutional ownership, profitability, dividends, analyst recommendations, valuation, risk and earnings.

Analyst Ratings

This is a summary of current ratings and recommmendations for Oculis and its rivals, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oculis 0 0 8 0 3.00
Oculis Competitors 6390 18218 43658 911 2.57

Oculis currently has a consensus price target of $30.17, suggesting a potential upside of 152.65%. As a group, “Pharmaceutical preparations” companies have a potential upside of 76.62%. Given Oculis’ stronger consensus rating and higher possible upside, equities analysts clearly believe Oculis is more favorable than its rivals.

Earnings and Valuation

This table compares Oculis and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Oculis $980,000.00 -$98.92 million -6.71
Oculis Competitors $1.65 billion $150.62 million -1.84

Oculis’ rivals have higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.


This table compares Oculis and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Oculis -6,712.02% -52.72% -43.72%
Oculis Competitors -3,062.12% -293.82% -34.22%

Volatility & Risk

Oculis has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500. Comparatively, Oculis’ rivals have a beta of 1.10, indicating that their average share price is 10% more volatile than the S&P 500.

Insider and Institutional Ownership

22.3% of Oculis shares are owned by institutional investors. Comparatively, 44.3% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 14.0% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.


Oculis rivals beat Oculis on 9 of the 13 factors compared.

About Oculis

(Get Free Report)

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with's FREE daily email newsletter.